Log In
Print this Print this

ATI-50001 (formerly A-201)

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionJanus kinase-1 (JAK-1) and JAK-3 inhibitor
Molecular Target Janus kinase-1 (JAK-1) ; Janus kinase-3 (JAK-3)
Mechanism of ActionJanus kinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationAlopecia
Indication DetailsTreat alopecia areata; Treat alopecia totalis; Treat alopecia universalis
Regulatory Designation
PartnerAclaris Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today